

A2 desferrioxamine (DFO); parathyroid hormone; anti-microbials, including, but not limited to anti-fungal agents; or any combination thereof.

IN THE CLAIMS:

Cancel claims 1-19 without prejudice.

Add claims 20-46 reading as follows:

20. A pharmacological composition comprising:

- (A) at least one biologically-active agent; and
(B) at least one carrier compound having the formula



or a salt thereof

wherein Ar is a substituted phenyl or naphthyl;

6-170208 R⁷ is selected from the group consisting of C₄ to C₂₀ alkyl, C₄ to C₂₀ alkenyl, phenyl, naphthyl, (C₁ to C₁₀ alkyl)phenyl, (C₁ to C₁₀ alkenyl)phenyl, (C₁ to C₁₀ alkyl)naphthyl, (C₁ to C₁₀ alkenyl) naphthyl, phenyl (C₁ to C₁₀ alkyl), phenyl (C₁ to C₁₀ alkenyl), naphthyl (C₁ to C₁₀ alkyl) and naphthyl (C₁ to C₁₀ alkenyl);

R⁷ is optionally substituted with C₁ to C₄ alkyl, C₁ to C₄ alkenyl, C₁ to C₄ alkoxy, -OH, -SH and -CO₂R⁹ or any combination thereof;

R⁷ is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof;

R⁸ is selected from the group consisting of hydrogen, C₁ to C₄ alkyl, C₁ to C₄ alkenyl, hydroxy, and C₁ to C₄ alkoxy; and

R⁹ is hydrogen, C₁ to C₄ alkyl, or C₁ to C₄ alkenyl;

with the proviso that the compounds are not substituted with an amino group in the position alpha to the acid group.

~~21.~~ The composition of claim 20, wherein Ar is substituted with at least one of C₁-C₅ alkyl, C₂-C₄ alkenyl, -F, -Cl, -OH, -SO₂, -COOH or -SO₃H.

~~22.~~ The composition of claim 21 wherein Ar is a substituted phenyl.

~~23.~~ The composition of claim 21, wherein Ar is a phenyl substituted with -Cl.

~~24.~~ The composition of claim 21, wherein Ar is a phenyl substituted with -F.

~~25.~~ The composition of claim 23, wherein R⁷ is selected from the group consisting of C₄ to C₂₀ alkyl, (C₁-C₁₀ alkyl)phenyl, and phenyl (C₁ to C₁₀ alkyl).

~~26.~~ The composition of claim 23, wherein R⁷ is C₄-C₂₀ alkyl.

~~27.~~ The composition of claim 26, wherein R⁷ is not substituted or interrupted.

~~28.~~ The composition of claim 27, wherein R⁸ is hydrogen.

132 ~~56~~ 29. ~~The composition of claim 20, wherein the biologically active agent comprises at least one peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, or lipid.~~

10 ~~30~~ 30. The composition of claim 29, wherein the biologically active agent is a peptide.

A3 11 ~~31~~ 31. The composition of claim 29, wherein the biologically active agent is a mucopolysaccharide.

1300551110701 ~~56~~ 133 ~~32~~ 32. ~~The composition according to claim 20, wherein the biologically active agent comprises human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine, parathyroid hormone, an antimicrobial, an antifungal agent or a combination thereof.~~

13 ~~33~~ 33. The composition according to claim 32, wherein said biologically-active agent comprises human growth hormone, an interferon, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, cromolyn sodium, parathyroid hormone, an antimicrobial or a combination thereof.

14 ~~34.~~ The composition according to claim 33, wherein said biologically-active agent comprises human growth hormone.

15 ~~35.~~ The composition according to claim 33, wherein said biologically-active agent comprises insulin.

16 ~~36.~~ The composition according to claim 33, wherein said biologically-active agent comprises heparin.

17 ~~37.~~ The composition according to claim 33, wherein said biologically-active agent comprises low molecular weight heparin.

18 ~~38.~~ The composition according to claim 33, wherein said biologically-active agent comprises calcitonin.

19 ~~39.~~ The composition according to claim 33, wherein said biologically-active agent comprises cromolyn sodium.

20 ~~40.~~ The composition according to claim 33, wherein said biologically-active agent comprises parathyroid hormone.

21 ~~41.~~ A dosage unit form comprising

B4
Cost

- (A) a pharmacological composition according to claim 20; and
- (B) (i) an excipient,
(ii) a diluent
(iii) a disintegrant
(iv) a lubricant,
(v) a plasticizer
(vi) a colorant
(vii) a dosing vehicle, or
(viii) any combination thereof..

22
42.

A dosage unit form according to claim 41, comprising a tablet, a capsule, or a liquid.

23
43.

A dosage unit form according to claim 41, wherein said dosing vehicle is selected from the group consisting of water, 1,2-propane diol, ethanol, and any combination thereof.

135
Sub

44. A method for preparing a pharmacological composition, said method comprising mixing:

- (A) at least one biologically-active agent;
(B) at least one carrier compound having the formula



wherein Ar is a substituted phenyl or naphthyl;

6-17-028
R⁷ is selected ^{from} ~~from~~ the group consisting of C₄ to C₂₀ alkyl, C₄ to C₂₀ alkenyl, phenyl, naphthyl, (C₁ to C₁₀ alkyl)phenyl, (C₁ to C₁₀ alkenyl)phenyl, (C₁ to C₁₀ alkyl)naphthyl, (C₁ to C₁₀ alkenyl) naphthyl, phenyl (C₁ to C₁₀ alkyl), phenyl (C₁ to C₁₀ alkenyl), naphthyl (C₁ to C₁₀ alkyl) and naphthyl (C₁ to C₁₀ alkenyl);

AB
R⁷ is optionally substituted with C₁ to C₄ alkyl, C₁ to C₄ alkenyl, C₁ to C₄ alkoxy, -OH, -SH and -CO₂R⁹ or any combination thereof;

R⁷ is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof;

R⁸ is selected from the group consisting of hydrogen, C₁ to C₄ alkyl, C₁ to C₄ alkenyl, hydroxy, and C₁ to C₄ alkoxy; and

R⁹ is hydrogen, C₁ to C₄ alkyl, or C₁ to C₄ alkenyl;

with the proviso that the compounds are not substituted with an amino group in the position alpha to the acid group; and

(C) optionally a dosing vehicle.

45. A method for administering a biologically-active agent to an animal in need of said agent, said method comprising administering orally to said animal a composition as defined in claim 20.

46. A method for administering a biologically-active agent to a mammal in need of said agent, said method comprising administering orally to said mammal a composition as defined in claim 20.